272BIO

Beeches Farm Road Maple Barn /

TN22 5QD Uckfield

GB

272BIO

Foundation date

19/07/2019

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

272BIO are developing biotherapeutics, using innovative technologies, for livestock and companion animal disorders. Applying novel technologies, we are able to reduce hitherto prohibitive production costs and produce affordable therapies.  VHH antibodies enable 272BIO to design bespoke drugs for optimal disease control.

Upcoming events

Latest news

  • argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia

    20 hours ago

  • Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

    Wednesday November 22nd 2023

  • argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis

    Thursday November 16th 2023